Panbela Therapeutics Inc.
712 Vista Blvd. Suite 305
Waconia
MN
United States
141 articles about Panbela Therapeutics Inc.
-
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025Trial's lower-than-expected event rate suggests improved survival outcomes
4/22/2024
Panbela Therapeutics, Inc. today announced that the interim data analysis for its ongoing ASPIRE trial is now expected to be available as soon as Q1 2025.
-
Panbela Announces Poster Presentation at American Association for Cancer Research:Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer models
4/18/2024
Panbela Therapeutics, Inc., a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer announces a poster presentation highlighting the results for ivospemin as a polyamine metabolism modulator in ovarian cancer at the American Association for Cancer Research, which took place April 10, 2024.
-
Panbela Announces Transfer to OTCQB Market
4/16/2024
Panbela Therapeutics, Inc., a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announced that its common stock has been approved for quotation on the OTCQB market.
-
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
3/26/2024
Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter and full year ended December 31, 2023.
-
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
3/12/2024
Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”) today announced that it will host a conference call on March 26, 2024, at 4:30 PM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2023.
-
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
2/15/2024
Panbela Therapeutics, Inc., a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announced that, has regained compliance with applicable listing standards of The Nasdaq Stock Market for bid price and publicly held shares.
-
Panbela Announces Closing of Approximately $9.0 Million Public Offering
2/1/2024
Panbela Therapeutics, Inc. today announced the closing of its previously announced public offering of (i) 4,375,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) two classes of warrants to purchase up to an aggregate of 8,750,000 shares of its common stock.
-
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
1/30/2024
Panbela Therapeutics, Inc today announced that an abstract for SBP-101, a proprietary polyamine analogue, has been accepted for poster presentation at the American Association for Cancer Research (AACR), which will be held April 5-10, 2024.
-
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
1/29/2024
Panbela Therapeutics, Inc. announced the pricing of a public offering of 4,375,000 shares of its common stock or pre-funded warrants in lieu thereof and two classes of warrants to purchase up to an aggregate of 8,750,000 shares of its common stock at a purchase price of $2.06 per share and associated Common Warrants.
-
Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum
1/25/2024
Panbela Therapeutics, Inc. announced it has reached 50% enrollment for its ASPIRE global clinical trial in the first-line treatment of metastatic pancreatic cancer.
-
Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
1/18/2024
Panbela Therapeutics, Inc., a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs announces the publication of clinical data from studies of CPP-1X or Eflornithine) in neuroblastoma.
-
Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024
1/16/2024
Panbela Therapeutics, Inc. announced that it will implement the previously announced and stockholder approved 1-for-20 reverse split of its common stock.
-
Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.0 Million Gross Proceeds Priced At-the-Market
12/21/2023
Panbela Therapeutics, Inc. today announced it has entered into agreements with certain holders of its existing warrants exercisable for 2,556,000 shares of its common stock.
-
Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric Neuroblastoma
12/18/2023
Panbela Therapeutics, Inc. (Nasdaq: PBLA) today announced that US WorldMeds®1 (USWM), a Kentucky-based specialty pharmaceutical company to whom it divested certain assets in its eflornithine pediatric neuroblastoma program, received FDA approval of its New Drug Application (NDA) for the use of eflornithine as a maintenance therapy for high-risk neuroblastoma patients who have achieved at least a partial response to certain prior therapies.
-
Panbela Announces Publication of Abstract Titled: Evaluation of Myeloma Cell Lines Viability Following Administration of SBP-101 and DFMO Polyamine Inhibitors
12/4/2023
Panbela Therapeutics, Inc today announces the publication of preclinical data from studies of ivospemin (also known as SBP-101) and eflornithine (also known as CPP-1X or DFMO) research in multiple myeloma (cell lines).
-
Panbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification
11/29/2023
Panbela Therapeutics, Inc. announces that the independent Data Safety Monitoring Board (DSMB) of the Phase 3 ASPIRE clinical trial for patients with untreated metastatic pancreatic ductal adenocarcinoma has completed its pre-specified review of safety data for treated patients.
-
Panbela Provides Business Update and Reports Q3 2023 Financial Results
11/9/2023
Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended September 30, 2023.
-
Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds Priced At-the-Market
11/3/2023
Panbela Therapeutics, Inc. announced it has entered into agreements with certain holders of its existing warrants exercisable for 2,130,000 shares of its common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $0.78 per share, in exchange for new warrants as described below.
-
Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves β Cell Function in Type 1 Diabetes
11/2/2023
Panbela Therapeutics, Inc . announces the publication of preclinical and clinical data from studies of CPP-1X (also known as α-Difluoromethylornithine (DFMO).
-
Panbela Announces Validation of European Patent in UK, Italy, Germany, France, and Spain for Claims of a Novel Process for the Production of SBP-101
10/31/2023
Panbela Therapeutics, Inc. announced validation for the European patent 2019213664 titled "METHODS FOR PRODUCING -3,8,13,18- TETRAAZAICOSANE-6,15-DIOL" in the United Kingdom, Italy, Germany, France, and Spain.